Characteristics of 78 eligible patients treated with RABVD
| Characteristic . | RABVD . |
|---|---|
| Total, N | 78 |
| Sex, n (%) | |
| Male | 40 (51) |
| Female | 38 (49) |
| Median age, y (range) | 32 (18-72) |
| Stage, n (%) | |
| II | 28 (36) |
| > 8 cm with B symptoms | 3 (4) |
| ≥ 10 cm or mediastinal ≥ 1/3 chest diameter | 23 (29) |
| Relapsed after previous primary radiation therapy | 2 (3) |
| III | 24 (31) |
| IV | 26 (33) |
| IPS, n (%) | |
| 0 | 6 (8) |
| 1 | 19 (24) |
| 2 | 18 (23) |
| 3 | 18 (23) |
| ≥ 4 | 17 (22) |
| CD20 status, n (%) | |
| Positive | 14 (18) |
| Negative | 56 (72) |
| Unknown | 8 (10) |
| Postchemotherapy radiation, n (%) | 26 (33) |
| Characteristic . | RABVD . |
|---|---|
| Total, N | 78 |
| Sex, n (%) | |
| Male | 40 (51) |
| Female | 38 (49) |
| Median age, y (range) | 32 (18-72) |
| Stage, n (%) | |
| II | 28 (36) |
| > 8 cm with B symptoms | 3 (4) |
| ≥ 10 cm or mediastinal ≥ 1/3 chest diameter | 23 (29) |
| Relapsed after previous primary radiation therapy | 2 (3) |
| III | 24 (31) |
| IV | 26 (33) |
| IPS, n (%) | |
| 0 | 6 (8) |
| 1 | 19 (24) |
| 2 | 18 (23) |
| 3 | 18 (23) |
| ≥ 4 | 17 (22) |
| CD20 status, n (%) | |
| Positive | 14 (18) |
| Negative | 56 (72) |
| Unknown | 8 (10) |
| Postchemotherapy radiation, n (%) | 26 (33) |